Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Represents the next generation of incretin-based therapies with potentially superior efficacy to semaglutide for weight loss.
A GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management. One of the most commercially successful peptide drugs in history.
Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, producing enhanced insulin secretion, appetite suppression, and metabolic improvements beyond what single-agonist drugs achieve.
Mimics the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system signaling. The result is improved blood sugar control and significant weight loss.
- Weight management
- Type 2 diabetes treatment
- Metabolic health improvement
- Weight management
- Type 2 diabetes treatment
- Blood sugar regulation
- Cardiovascular risk reduction
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis risk
- Injection site reactions
- Potential thyroid concerns
- Nausea and vomiting (common, usually transient)
- Pancreatitis (rare but serious)
- Gallbladder issues
- Potential thyroid tumor risk (animal studies)
- Muscle mass loss alongside fat loss
- GI side effects (diarrhea, constipation)
FDA-approved as Mounjaro (diabetes, 2022) and Zepbound (weight management, 2023).
FDA-approved as Ozempic (diabetes, 2017), Wegovy (weight management, 2021), and Rybelsus (oral, diabetes, 2019). Multiple dosage forms and indications approved.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.